20.500.12556/RUL-154199 Comparison of nucleosome, ferritin and LDH levels in blood with clinical response before and after electrochemotherapy combined with IL-12 gene electrotransfer for the treatment of mast cell tumours in dogs Electrochemotherapy (ECT) in combination with the gene electrotransfer of interleukin 12 (IL-12 GET) has been successfully used in veterinary medicine for the treatment of mast cell tumours (MCT), but the biomarkers that could predict response to this treatment have not yet been investigated. The aim of this study was to determine the plasma nucleosome and serum ferritin concentrations, as well as the lactate dehydrogenase (LDH) activity, in the serum of treated patients before and one and six months after treatment to evaluate their utility as potential biomarkers that could predict response to the combined treatment. The study was conducted in 48 patients with a total of 86 MCTs that we treated with the combined treatment. The blood samples used for analysing the potential predictive biomarkers were taken before treatment and one and six months after treatment, when the response to treatment was also assessed. The Nu. Q® Vet Cancer Test, the Canine Ferritin ELISA Kit, and the RX Daytona+ automated biochemical analyser were used to analyse the blood samples. The results showed that the plasma nucleosome concentration (before treatment (BT): 32.84 ng/mL (median); one month after treatment (1 M AT): 58.89 ng/mL (median); p = 0.010) and serum LDH activity (BT: 59.75 U/L (median); 1 M AT: 107.5 U/L (median); p = 0.012) increased significantly one month after treatment and that the increase correlated significantly with the presence of a more pronounced local reaction (necrosis, swelling, etc.) at that time point for both markers (nucleosome: BT (necrosis): 21.61 ng/mL (median); 1 M AT (necrosis): 69.92 ng/mL (median), p = 0.030; LDH: BT (necrosis): 54.75 U/L (median); 1 M AT (necrosis): 100.3 U/L (median), p = 0.048). Therefore, both the plasma nucleosome concentration and serum LDH activity could serve as early indicators of the effect of the treatment. In this context, the serum ferritin concentration showed no significant predictive potential for treatment response (p > 0.999 for all comparisons). In conclusion, this study provides some new and important observations on the use of predictive biomarkers in veterinary oncology. Furthermore, it emphasises the need for the continued identification and validation of potential predictive biomarkers in dogs with MCT and other malignancies undergoing ECT treatment in combination with IL-12 GET to ultimately improve treatment outcomes. electrochemotherapy Interleukin-12 mast cells neoplasms biomarkers nucleosomes ferritins L-Lactate dehydrogenase true false true Angleški jezik Ni določen Članek v reviji 2024-01-31 14:22:52 2024-01-31 14:23:00 2024-02-02 03:21:24 0000-00-00 00:00:00 2024 0 0 25 str. iss. 3, art. 438 Vol. 14 2024 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 636.09:616 2076-2615 10.3390/ani14030438 182891779 Comparison-Vilfan.pdf Comparison-Vilfan.pdf 1 51AAC8649742A6F00D5A87DB0812ACD7 436c6512956e6f87b36fc60dfa6bac385c964b5bb22373edf924e7840ba6c76b 91bd0647-c03c-11ee-a648-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=180446 https://www.mdpi.com/2076-2615/14/3/438 1 daa44978-c03b-11ee-a648-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=180445 Veterinarska fakulteta 0 0 0